Joint Investment in IOPtima Subsidiary

BioLight announced today that it has entered into a joint financing agreement with two Asia-based venture capital firms, pursuant to which BioLight and the New Investors will make a direct equity investment in BioLight’s  IOPtima Ltd. subsidiary via a private placement. The financing will help IOPtima to continue the global …

Continue reading

Second Quarter 2015 Financial Results

BioLight today reported operational and financial results for the second quarter ended June 30, 2015.

Operational Highlights:

  • Completed an upsized private investment and signed a strategic partnership with Rock-One International Holdings Ltd. designed to help BioLight maximize its presence within China, the second largest healthcare market in the world after the …

    Continue reading

Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ

BioLight today announced that its cancer diagnostics subsidiary, Micromedic Technologies, has identified several new genetic markers with high potential to predict necrosis of the jawbone in patients treated with bisphosphonate drugs and was able to repeat findings from a previous study for one significant marker in a larger and more diversified group …

Continue reading

Collaboration with Ora, Inc. for TeaRx™

BioLight today announced that it has expanded its relationship with Ora, Inc., a world-leading independent, full-service ophthalmic contract research organization and product development firm, via the signing of a collaboration agreement pursuant to which the companies will work together to advance the clinical, regulatory and commercial development of BioLight’s TeaRx™ …

Continue reading